Summit Therapeutics

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Company Growth (employees)
Type
Public
HQ
Milton, GB
Founded
2003
Size (employees)
44 (est)+19%
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton and Cambridge
Milton, GB (HQ)
Park House Park Dr 85b
Cambridge, US
1 Broadway

Summit Therapeutics Financials and Metrics

Summit Therapeutics Financials

Summit Therapeutics's revenue was reported to be £2.3 m in FY, 2017 which is a 59% increase from the previous period.
GBP

Revenue (FY, 2017)

2.3 m

Net income (FY, 2017)

(21.4 m)

EBITDA (FY, 2017)

(24.8 m)

EBIT (FY, 2017)

(24.9 m)

Market capitalization (31-Oct-2017)

96 m

Closing share price (31-Oct-2017)

1.6

Cash (31-Jan-2017)

28.1 m
Summit Therapeutics's current market capitalization is £96 m.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3 m1.8 m189 k763 k1.8 m1.8 m1.8 m2.1 m1.5 m2.3 m

Revenue growth, %

16%(32%)

Cost of goods sold

1.6 m1.1 m

Gross profit

1.4 m773 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.1 m2.7 m6.1 m3.3 m2.1 m3.4 m2 m11.3 m16.3 m28.1 m

Accounts Receivable

189 k651 k41 k32 k47 k51 k

Inventories

337 k391 k

Current Assets

12.7 m5.4 m6.6 m3.7 m2.6 m4.2 m3.1 m15.2 m20.8 m33.3 m
    GBPY, 2017

    Revenue/Employee

    56.9 k

    Financial Leverage

    -10.8 x
    Show all financial metrics

    Summit Therapeutics Market Value History

    Summit Therapeutics's Web-traffic and Trends

    Summit Therapeutics Online and Social Media Presence

    Summit Therapeutics Company Life and Culture

    You may also be interested in